Cleveland Diagnostics, Inc.

Are you interested in joining a team dedicated to early cancer detection? We are hiring for various roles! If you share our commitment to innovation and excellence in diagnostics, we invite you to visit our careers page to explore our open opportunities. Learn more about our open roles here: https://bit.ly/3XQY8hL #werehiring #careers #hiring

Significant disparities in prostate cancer incidence and outcomes persist across different races and socioeconomic statuses. In this pharmaphorum article, Cleveland Diagnostics’ CEO Dr. Arnon Chait, discusses the need for accessible, accurate, and patient-friendly early screening methods to address these inequities. https://bit.ly/4f51Hag #prostatecancer #earlycancerdetection #cancerscreening

What’s the difference between IsoPSA and PSA? Prostate cancer can elevate PSA levels, but so can benign factors such as prostate enlargement, infections, sexual activity, and even a prostate exam. As a result, up to 75% of prostate biopsies are negative for high-grade cancer. The IsoPSA test helps identify men who may not need a biopsy by assessing structural differences in PSA proteins that are expressed by cancer cells Learn more about IsoPSA here: https://bit.ly/3TLil4T #prostatecancer #cancerdiagnostics

A study by the University of Oxford, Oxford University Hospitals, and NIHR Oxford Biomedical Research Centre has found a new method for identifying prostate cancer cells. This method will help surgeons visualize and remove cancer cells that might otherwise be missed while preserving healthy tissue. A recent study found that a molecule combination called IR800-IAB2M (a fluorescent dye) has the ability to stick to prostate cancer cells and highlight areas not visible to the human eye. Read more from Genetic Engineering & Biotechnology News here: https://bit.ly/3Lfbz3n #prostatecancer #urology

In this interview with Urology Times, Jason Hafron MD, Chief Medical Officer and Medical Director of Clinical Research at the Michigan Institute Of Urology, discusses the role of IsoPSA in assessing the risk for high-grade prostate cancer and how it fits into the current diagnostic and treatment landscape. Dr. Hafron also delves into the study “Using IsoPSA With Prostate Imaging Reporting and Data System Score May Help Refine Biopsy Decision Making in Patients With Elevated PSA,” which shows how combining mpMRI with IsoPSA can improve biopsy decision-making. https://bit.ly/3ROKLuB #prostatecancer

Our Men’s Health Month Innovation Spotlight Series highlights innovations advancing men’s health this June. Along with IsoPSA, prostate-specific membrane antigen (PSMA), PET imaging is another innovation that has enhanced prostate cancer care in recent years. Jason Hafron, MD, Chief Medical Officer and Medical Director of Clinical Research at the Michigan Institute Of Urology, shares more about this recent innovation that is helping to transform patient care. Watch here: #MensHealthMonth #ProstateCancer #Urology

Throughout June, during our Men’s Health Month Innovation Spotlight series, we’re highlighting advancements in men’s health, including mental health. According to the World Health Organization, almost 800,000 people die by suicide every year, with men making up 75% of that figure. Over the years, the stigma around seeking help for mental health (viewing this as a sign of weakness or not masculine) has contributed to many men not reaching out when they need it. Online therapy and resources, like HeadsUpGuys, are bridging the gap and providing support for men living with mental health issues, including anxiety and depression. From self-guided courses to help finding a therapist, the organization helps break down the stigma of mental health so men can get the help they need. To learn more about HeadsUpGuys, visit their website here: https://bit.ly/3VU758C #MensHealthMonth #Depression #mentalhealth

Continuing with our Men’s Health Month Innovation Series, Aaron Berger, MD, Chief Medical Officer of Associated Urological Specialists, highlights the benefits of IsoPSA testing for prostate cancer. Watch below. #prostatecancer #cancerdiagnostics #urology #MensHealthMonth

Join us today for Today's Clinical Lab Cancer Research and Diagnostics Digital Forum! Cleveland Diagnostics' VP of R&D, Dr. Erez Podoly, will discuss the latest breakthroughs in prostate cancer at 11 am ET. There’s still time to register here: https://bit.ly/3XnJf63 #ProstateCancer #Urology

We look forward to attending Today's Clinical Lab Cancer Research and Diagnostics Digital Forum next week! Don’t miss our VP of R&D, Dr. Erez Podoly’s presentation on Tuesday, June 18th at 11 am ET, where he will discuss recent breakthroughs in prostate cancer. Register now to save your spot: https://lnkd.in/gHDhwx5T #ProstateCancer #Urology